Context: Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for treating diabetes, have become mega-blockbuster drugs thanks to their second medical use in weight management. Denmark’s Novo Nordisk and the U.S.’s Eli Lilly and Company are the two dominant originators in the GLP-1 market; both are facing expiration of key GLP-1-related patents, with generic competition waiting in the wings (June 16, 2025 ip fray article).
To Read The Full Story
Continue reading your article with a Membership
Counsel
In the District of Delaware, Eli Lilly is being represented by Morris, Nichols, Arsht & Tunnell’s Rodger D. Smith II, Jeremy A. Tigan, and Anthony D. Raucci; and Latham & Watkins’ Michael A. Morin, David P. Frazier, Ashley M. Fry, Michelle L. Ernst, Geoffrey A. Kirsner, Alyssa A. Dolan, and Darpan Patel.
In the Western District of Pennsylvania, Novo Nordisk is being represented by Marcus & Shapira’s Leland P. Schermer; and a team at Groombridge, Wu, Baughman & Stone: Nicholas Groombridge, Peter Sandel, Jenny Wu, Daniel J. Klein, Joshua Reich, Ariella C. Barel, Joshua Rosefelt, and Alyssa Ertel.